Regular surveillance is associated with improved survival after nasopharyngeal cancer treatment

Among 8,798 patients with nasopharyngeal carcinoma, regular surveillance was associated with better overall survival, particularly when distant-site imaging was performed.

KEY POINTS

  • This retrospective single-center study analyzed 8,798 patients with stage I–IVA non-metastatic nasopharyngeal carcinoma who achieved complete remission after curative-intent treatment and remained disease-free for at least one year. All received IMRT with or without chemotherapy, and the median follow-up was 64.8 months.
  • Surveillance intensity was defined using a one-year landmark analysis to reduce guarantee-time bias. Patients attending at least four follow-up visits during the first year were classified as regularly surveilled (n=4,078), whereas those attending fewer than four visits were classified as irregularly surveilled (n=4,720).
  • Regular surveillance was associated with improved overall survival after multivariable adjustment (HR 0.86, 95% CI 0.74–0.99; p=0.032), corresponding to a 14% lower observed hazard of death. Recurrence rates were similar between groups (14.7% vs 14.9%), indicating that the association was not driven by a lower frequency of recurrence.
  • Distant-site imaging surveillance using CT, MRI or ultrasound of the chest, abdomen or pelvis showed the strongest association with overall survival (HR 0.69, 95% CI 0.57–0.82; p<0.001). In contrast, local nasopharyngeal imaging (HR 1.36; p=0.140) and regional neck imaging (HR 0.85; p=0.428) were not significantly associated with survival.
  • Patients receiving regular surveillance had more favorable disease extent at recurrence. Stage I recurrence occurred in 34.7% versus 27.1%, while stage IV recurrence occurred in 44.6% versus 48.6%; among those developing distant metastases, single-organ involvement was more common with regular surveillance (79.3% vs 62.2%).
  • Survival after recurrence was also longer among regularly surveilled patients (adjusted HR 0.68, 95% CI 0.58–0.80; p<0.001). Subgroup analyses suggested a stronger association in patients with stage IV disease at diagnosis (HR 0.82; p=0.047) and elevated pretreatment EBV DNA (HR 0.79; p=0.007), although these findings remain observational.
  • The study did not capture salvage treatment after recurrence, preventing assessment of whether earlier detection led directly to more effective intervention. Residual confounding from socioeconomic status, healthcare engagement and treatment adherence remains possible, and the one-year landmark design excludes patients experiencing early recurrence or death.

CLINICAL TAKEAWAY

These findings support further investigation of structured, risk-adapted surveillance after definitive treatment for nasopharyngeal carcinoma, particularly imaging aimed at detecting distant recurrence. The association with improved survival is clinically important but cannot establish that more frequent imaging itself reduces mortality, and optimal imaging modalities, intervals and cost-effectiveness remain undefined.

SOURCE

Radiotherapy and Oncology

Browse more research Suggest a correction